State Street
FDMT icon

State Street’s 4D Molecular Therapeutics FDMT Stock Holding History

State Street’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.7M Buy
2,911,109
+203,234
+8% +$1.98M ﹤0.01% 2007
2026
Q1 		$25.2M Buy
2,707,875
+18,995
+0.7% +$165K ﹤0.01% 2122
2025
Q4 		$20.2M Buy
2,688,880
+1,785,106
+198% +$18.1M ﹤0.01% 2271
2025
Q3 		$7.85M Sell
903,774
-58,188
-6% -$348K ﹤0.01% 2772
2025
Q2 		$3.57M Sell
961,962
-65,988
-6% -$232K ﹤0.01% 3078
2025
Q1 		$3.32M Sell
1,027,950
-84,773
-8% -$399K ﹤0.01% 3049
2024
Q4 		$6.2M Sell
1,112,723
-1,003,785
-47% -$7.88M ﹤0.01% 2872
2024
Q3 		$22.9M Buy
2,116,508
+37,232
+2% +$618K ﹤0.01% 2128
2024
Q2 		$43.6M Sell
2,079,276
-98,954
-5% -$2.48M ﹤0.01% 1740
2024
Q1 		$69.4M Buy
2,178,230
+654,240
+43% +$16.7M ﹤0.01% 1541
2023
Q4 		$30.9M Sell
1,523,990
-193,130
-11% -$2.54M ﹤0.01% 1961
2023
Q3 		$21.9M Sell
1,717,120
-333,310
-16% -$5.57M ﹤0.01% 2123
2023
Q2 		$37.1M Buy
2,050,430
+8,241
+0.4% +$152K ﹤0.01% 1852
2023
Q1 		$35.1M Buy
2,042,189
+807,031
+65% +$15.7M ﹤0.01% 1869
2022
Q4 		$27.4M Buy
1,235,158
+557,982
+82% +$8.62M ﹤0.01% 2020
2022
Q3 		$5.44M Buy
677,176
+44,651
+7% +$404K ﹤0.01% 3015
2022
Q2 		$4.42M Sell
632,525
-856,846
-58% -$8.33M ﹤0.01% 3156
2022
Q1 		$22.5M Buy
1,489,371
+229,711
+18% +$3.61M ﹤0.01% 2314
2021
Q4 		$27.6M Buy
1,259,660
+939,998
+294% +$23M ﹤0.01% 2231
2021
Q3 		$8.62M Buy
319,662
+154,170
+93% +$4.4M ﹤0.01% 2970
2021
Q2 		$3.98M Buy
165,492
+58,659
+55% +$1.8M ﹤0.01% 3349
2021
Q1 		$4.63M Buy
+106,833
New +$4.73M ﹤0.01% 3085

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street's FDMT Position: Q2 2026 in Review

State Street increased its 4D Molecular Therapeutics (FDMT) stake by 7.5% in Q2 2026, buying an estimated $1.98M and bringing the position to 2,911,109 shares worth $38.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2007.

State Street first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $69.4M in Q1 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • State Street held 2,911,109 shares of 4D Molecular Therapeutics worth $38.7M as of Q2 2026.
  • State Street bought 203,234 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.98M.
  • 4D Molecular Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2007 holding.
  • State Street first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • State Street's 4D Molecular Therapeutics position peaked at $69.4M in Q1 2024.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.